What did Agios Pharmaceuticals (NASDAQ:AGIO) announce regarding tebapivat for LR-MDS?

Agios Pharmaceuticals announced it will discontinue the clinical development of tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b trial failed to meet the company’s predefined threshold for advancement. Shares fell approximately 13% following the announcement.

Why did Agios (NASDAQ:AGIO) discontinue tebapivat in LR-MDS?

The Phase 2b study did not achieve the primary endpoint of transfusion independence in a sufficient proportion of patients. Although tebapivat showed biological activity, the clinical benefit was not strong enough to justify further development in this indication.

What was the design of the Phase 2b LR-MDS trial?

The open-label, multicenter trial lasted 24 weeks and enrolled 65 patients with LR-MDS and anemia. Participants received once-daily tebapivat at doses of 10 mg, 15 mg, or 20 mg, and the primary endpoint required at least eight consecutive weeks without a blood transfusion.

How did tebapivat perform in terms of safety?

The oral pyruvate kinase activator was well tolerated across all dose levels, and no new safety signals were observed. This suggests that the drug remains safe for further investigation in other indications.

Will Agios (NASDAQ:AGIO) abandon tebapivat entirely?

No. While development for LR-MDS is discontinued, the company plans to focus tebapivat on other high-priority indications, such as sickle cell disease, where a Phase 2 trial has already completed enrollment.

Image for illustrative purposes only. Not a real photo.

Agios discontinues tebapivat program in lower-risk myelodysplastic syndromes after Phase 2b trial fails

Written by Jon CuthbertPublished May. 29 2026Last Updated May. 29 2026

Agios Pharmaceuticals (NASDAQ:AGIO) announced that it will discontinue the clinical development of its investigational oral therapy tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b study failed to meet its predefined threshold for advancement.

Following the disclosure of the topline results, shares of the Cambridge, Massachusetts-based biopharmaceutical firm declined approximately 13% in Friday trading.

The open-label, multicenter, 24-week trial evaluated the efficacy and safety of once-daily tebapivat at doses of 10 mg, 15 mg, and 20 mg in 65 patients diagnosed with LR-MDS and anemia.

The primary endpoint of the study was transfusion independence, which required patients to go at least eight consecutive weeks without a blood transfusion during the 24-week treatment period.

Although Agios reported that tebapivat demonstrated evidence of biological activity, the clinical benefit was not observed in a large enough proportion of participants to meet the company's internal criteria for further development.

Regarding safety, the next-generation oral pyruvate kinase activator remained well tolerated across all investigated dose levels, and investigators observed no new safety signals during the evaluation period.

Sarah Gheuens, Chief Medical Officer and Head of R&D at Agios, stated that the trial results underscore the underlying biological complexity of lower-risk myelodysplastic syndromes as well as the ongoing challenges in identifying the specific patient populations most likely to benefit from the therapy.

Agios will shift its primary focus for the molecule toward other high-priority indications within its rare hematologic portfolio.

The company continues to see therapeutic potential for tebapivat in sickle cell disease, where a Phase 2 trial has already completed enrollment.

Topline data from that sickle cell evaluation remain on track for release in the second half of 2026.